Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | DHODH | Q02127 | 15/20 | 0.62 |
| ▸ | PTGFR | P43088 | 2/20 | 0.52 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202086 | 0.93 | PDE10A (0.63) | PDE10ATSHRDHODHDHFRALKBH5 | |
| SCHEMBL5200915 | 0.88 | DHODH (0.62) | PDE10ATSHRDHODHPTGFRNPC1 | |
| SCHEMBL2807617 | 0.84 | PDE10A (0.77) | PDE10ATSHRDHODHDHFRALKBH5 | |
| SCHEMBL18075791 | 0.83 | PDE10A (0.75) | PDE10ATSHRDHODHPTGFRDHFR | |
| SCHEMBL2371903 | 0.79 | DHODH (0.61) | PDE10ATSHRDHODHPTGFR | |
| SCHEMBL17593890 | 0.79 | DHODH (0.72) | PDE10ATSHRDHODHPTGFR | |
| SCHEMBL5425219 | 0.79 | DHODH (0.72) | PDE10ATSHRDHODHDHFRALKBH5 | |
| SCHEMBL17594005 | 0.79 | DHODH (0.94) | PDE10ATSHRDHODHPTGFRDHFR | |
| SCHEMBL14553153 | 0.78 | DHODH (0.70) | PDE10ATSHRDHODHDHFRALKBH5 | |
| SCHEMBL18075862 | 0.78 | DHODH (0.70) | PDE10ATSHRDHODHPTGFRDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377555-B1 | A DIOXINO[2,3-G]QUINOLINE-9-CARBOXYLIC ACID DERIVATIVE AS NK3 RECEPTOR ANTAGONIST | GLAXOSMITHKLINE SPA (IT) | 2007-01-24 | — | — | EP | disclosed |
| US-20060223819-A1 | Quinoline Derivatives as NK-3 Antagonists | GlaxoSmithKline S.P.A. & Laboratoire | 2006-10-05 | — | — | US | disclosed |
| US-20050182093-A1 | Novel compounds | GLAXOSMITHKLINE S.P.A. | 2005-08-18 | — | — | US | disclosed |
| US-20040152730-A1 | Novel compounds | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-05 | — | — | US | disclosed |
| US-20040097518-A1 | Quinoline derivatives as nk-3 antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2004-05-20 | — | — | US | disclosed |
| EP-1377555-A1 | NOVEL COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2004-01-07 | — | — | EP | disclosed |
| EP-1351953-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002083645-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002044165-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223819-A1 | Quinoline Derivatives as NK-3 Antagonists | KCNK3, KCNQ3, KCNN3 | PDE10A 1613/4885TSHR 2938/4885DHODH 1163/4885 |
| US-20050182093-A1 | Novel compounds | SLC10A1, AVPR2, REN | PDE10A 165/4885TSHR 4222/4885DHODH 902/4885 |
| US-20040097518-A1 | Quinoline derivatives as nk-3 antagonists | KCNK3, KCNQ3, KCNN3 | PDE10A 1730/4885TSHR 2963/4885DHODH 1238/4885 |
| US-20040152730-A1 | Novel compounds | SLC10A1, AVPR2, REN | PDE10A 165/4885TSHR 4222/4885DHODH 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.